Mylan Institutional, Inc. 2025-03-26 Health serious FDA
Health · FDA · Recall #FDA-D-0291-2025
Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister… Recall
Issued March 26, 2025 · Mylan Institutional, Inc.
In March 2025, Mylan Institutional, Inc. recalled the Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Super-Potent Drug: Out of specification potency results were obtained.
What you should do
- 1 Stop using Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Mylan Institutional, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Mylan Institutional, Inc.
- Category
- Health
- Recall date
- March 26, 2025
- Units affected
- Not reported
- Sold at
- Nationwide in the USA
- Recall number
- FDA-D-0291-2025
- Made in
- United States
- Issuing agency
- FDA
In context
- Mylan Institutional, Inc. has 7 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 691st Health recall we've logged in 2025.